Kala Bio KALA
NASDAQ KALA
$0.38 -0.04 (-9.52%)
At close: Oct 2, 2026 · 4:00 PM EDT

Kala Bio (KALA) Asset Writedowns and Impairment (2025)

Updated

Kala Bio's Asset Writedowns and Impairment was $1.41 million in FY2025.

Analysis

Kala Bio (KALA) Asset Writedowns and Impairment (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Kala Bio 5.81 Mn 5.81 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 1.41 Mn
API Access

Kala Bio Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=KALA&period=max&api_key=YOUR_API_KEY